ChemDiv, Inc. and Lilly have expanded their drug discovery collaboration through 2010. The two companies will identify and develop leads for an additional therapeutic target using ChemDiv's small molecule Resources and Discovery outSource platforms.
The collaboration began in January 2004 to discover and develop leads and research tools across multiple therapeutic areas. With this agreement, Lilly has continued access to ChemDiv's Discovery outSource services for preclinical and clinical development, with expertise in CNS, oncology, inflammation and metabolic disorders. The therapeutic target and financial terms were not disclosed.
"We are pleased to extend our successful collaboration with Lilly with a new therapeutic target," said Ron Demuth, senior vice president of ChemDiv. "We are delighted to have this opportunity to deliver superior value for our partner's R&D portfolio."
Read Lilly's profile in this year's Top 20 Pharma Report!
Sign up today for Contracting & Outsourcing 2009!